Fox-Fordyce disease (apocrine miliaria)

Meet the patient

A 28-year-old woman reports three years of intense, sleep-disrupting itch in both axillae, worse in the week before her period. The axillary skin is studded with dozens of firm, dome-shaped, skin-coloured papules, one to three millimetres across, each overlying a hairless follicle — and the axilla is conspicuously dry. She has tried five deodorants and two antiperspirants; none helped.^[1]

Two features should make you put down the deodorant and pick up the diagnosis: the distribution on apocrine skin in a reproductive-age woman, and the triad of pruritic papules, anhidrosis, and patchy axillary hair loss. Hold those two and the rest of the topic slots into place.^[1]

One anatomy fact explains the whole disease

The apocrine sweat duct empties into the hair follicle — not onto the skin surface. That single difference from the eccrine duct (which opens directly onto the epidermis) is the key that unlocks every clinical feature of Fox-Fordyce.^[3]

Because the duct shares the follicle, a keratin plug at the infundibular entry dams up apocrine secretion, the duct dilates and eventually ruptures, and the extravasated secretion fires a perifollicular lymphohistiocytic reaction studded with foam cells — lipid-laden macrophages that have gorged on apocrine lipid. That same shared follicle is why the overlying hair is shed and the affected skin turns anhidrotic.^[1]

Think of it as miliaria, but apocrine. Eccrine miliaria (prickly heat) obstructs the duct that opens on the surface and so spreads wherever sweat runs; Fox-Fordyce obstructs the duct that enters the follicle and so confines itself to apocrine territory.^[3]

Etymology for viva gold: the disease carries two surnames — George Henry Fox and John Addison Fordyce, the American dermatologists who described it in 1902 in two young women with intensely itchy axillary papules.^[5]

The AAA-P distribution — apocrine skin only

Lesions never stray outside apocrine gland-bearing skin. That geographic rule is the fastest way to confirm the diagnosis at the bedside, and the fastest way to refute it when papules appear elsewhere.^[1]

The classic trap: papules on the upper arms, forearms, or face are not Fox-Fordyce. Stop, reconsider the diagnosis, and look for folliculitis, miliaria rubra, scabies, or Darier disease before reaching for the clindamycin.^[1]

Who gets it — and why women 15 to 35

The tight demographic is the single strongest clue after the distribution. Fox-Fordyce is overwhelmingly a disease of post-pubertal women of reproductive age, with a female-to-male ratio of roughly nine to one.^[1]

^[1]

Why women, why this age? Apocrine glands are quiescent until puberty, when androgens (testosterone, dihydrotestosterone) switch them on. Before puberty the duct carries no secretion, so the disease cannot exist; after menopause glands involute and established disease often remits.^[1]

The premenstrual flare and the improvement in pregnancy point to the oestrogen-androgen balance modulating ductal keratinisation and gland output. The therapeutic success of the combined oral contraceptive pill with an anti-androgenic progestin, and of oral isotretinoin (which shrinks sebaceous and apocrine glands), confirms the hormonal driver.^[1][2]

The face-off — Fox-Fordyce versus hidradenitis suppurativa

The two diseases share a neighbourhood and a pathogenic verb — obstruction then rupture — but the symptom splits them at the bedside. Fox-Fordyce itches; hidradenitis suppurativa hurts.^[1]

^[1]

One-line discriminator: pruritus means Fox-Fordyce, pain means HS — and sinus tracts mean HS alone. The moment a putative Fox-Fordyce patient grows painful nodules, abscesses, or ropelike sinus tracks, the diagnosis is wrong: cross over to the hidradenitis pathway.^[1]

Where Fox-Fordyce sits on the follicular occlusion spectrum

Fox-Fordyce occupies the benign, non-scarring end of the follicular occlusion spectrum. The shared verb is obstruction then rupture of the pilosebaceous-folliculo-apocrine unit; what changes is how destructive the rupture is.^[1]

^[1]

Diagnose at the bedside — biopsy only when it does not fit

Fox-Fordyce is a clinical diagnosis. The stereotyped picture — a reproductive-age woman with itchy dome-shaped follicular papules, anhidrosis, and hair loss on apocrine skin — is enough. Reach for the biopsy punch only when the picture is atypical or the disease refuses first-line therapy.^[1]

When you do biopsy, hunt for the histological triad: apocrine duct spongiosis at the intra-epidermal duct entry, a parakeratotic plug in the infundibulum, and a dilated duct or retention cyst filled with secretion and foam cells. A single non-diagnostic biopsy does not exclude the disease — the duct is small and sampling is patchy, so serial sectioning or a re-biopsy of a fresh papule may be needed.^[3]

Dermoscopy is the non-invasive confirm: perifollicular papules with a central keratotic plug, sparse or absent hair within each papule, and a pale yellowish background matching the retention cyst — and none of the vessels of a basal cell carcinoma or melanocytic lesion.^[4]

Two cheap bedside tests settle the common mimics. Wood's lamp showing coral-red fluorescence is erythrasma, not Fox-Fordyce; a bacterial swab of a crusted lesion catches the staphylococcal secondary infection that changes management.^[1]

The treatment ladder — clindamycin and retinoid first

No treatment reliably cures Fox-Fordyce. The goal is control of pruritus and papule count with the least invasive effective regimen, escalating rung by rung.^[1]

^[1]

First line — topical clindamycin plus a topical retinoid

Topical clindamycin 1 percent lotion twice daily is the anti-inflammatory and antibacterial foundation, paired with a topical retinoid — tretinoin 0.025 to 0.1 percent nocte, or adapalene 0.1 percent gel nocte — to dissolve the keratin plug at the duct entry. Add a short course of a topical corticosteroid (betamethasone valerate 0.1 percent or clobetasol propionate 0.05 percent twice daily for two to four weeks) to settle acute itch, then step down to a calcineurin inhibitor for maintenance.^[1]

The classic trap: the axilla is thin, intertriginous skin. A potent steroid used for months will trade itch for atrophy and striae. Limit daily potent steroid use to two to four weeks, then switch to tacrolimus 0.1 percent ointment or step down to hydrocortisone 1 percent.^[1]

A few stubborn papules that ignore topical therapy can be injected with an intralesional corticosteroid, which appears among the reported treatment options.^[1][9]

Second line — the hormonal lever

For disease with a clear premenstrual flare, hormonal manipulation is tempting, and the combined oral contraceptive pill appears among the reported treatment options — but no hormonal regimen is established therapy, and responses across the small published series have been inconsistent.^[1][9]

Everyone forgets: the OCP usually improves Fox-Fordyce, but it has paradoxically triggered the disease in case reports. Review the response at three months and switch or stop the pill if the patient is worse. Check the standard contraindications first — migraine with aura, a smoker over 35, prior venous thromboembolism.^[1]

Third line — isotretinoin and the procedural options

Oral isotretinoin gave temporary relief to a male patient with refractory disease and sits among the reported systemic options, but its effect wanes once the drug is stopped.^[10]

Consultant confession: isotretinoin is most needed in precisely the population it is most dangerous — women of reproductive age. It is Category X and teratogenic, so two methods of contraception and pregnancy testing before, during, and after therapy are non-negotiable, and a paradoxical initial flare may need a short oral prednisolone cover.^[2]

When drugs fail, the procedural shelf holds botulinum toxin type A, which relieved refractory pruritic disease in published case reports, fractional carbon dioxide laser treatment, electrocauterisation, and excision — each described in only small numbers of patients.^[11][12][9]

^{[6] [7] [8] [9] [11] [12]}

Pregnancy, menopause, and the men who get it

Fox-Fordyce usually improves in pregnancy (high oestrogen and progesterone suppress apocrine secretion) and often remits after the menopause as the glands involute. New-onset disease in a post-menopausal woman is rare enough to question the diagnosis — consider contact dermatitis, scabies, Darier disease, lichen simplex chronicus, and biopsy if the morphology is atypical.^[1]

In pregnancy, keep it conservative: topical clindamycin 1 percent is safe; topical and oral retinoids are Category X and absolutely forbidden; use only low to moderate potency topical steroids in short courses; the OCP is contraindicated.^[1]

Fox-Fordyce in men is rare — usually axillary and perineal disease in a young, often obese or hirsute man, without the premenstrual pattern and with a poorer response. The OCP is obviously not an option, so lean on topical clindamycin plus retinoid, intralesional steroid, isotretinoin, and procedural options, and treat any underlying hyperandrogenism.^[2]

The dangerous-mimic checklist — when it is not Fox-Fordyce

Four findings should make you abandon Fox-Fordyce and reconsider, because each points to a different and more consequential diagnosis.^[1]

The single most common pitfall: mistaking hidradenitis suppurativa for Fox-Fordyce (or vice versa). The cardinal discriminator — pruritus versus pain, with sinus tracts and scarring absent in Fox-Fordyce and present in HS — resolves it at the bedside.^[1]

Ward-round test

A 24-year-old woman has intensely itchy, dome-shaped, skin-coloured papules in both axillae, with reduced axillary sweating and patchy hair loss that worsens premenstrually. Diagnosis and first-line treatment?ShowHide

This is classic Fox-Fordyce disease (apocrine miliaria): apocrine-skin distribution, reproductive-age woman, the triad of pruritic papules plus anhidrosis plus hair loss, and a premenstrual flare. First line is topical clindamycin 1 percent lotion twice daily plus a topical retinoid (tretinoin 0.025 to 0.1 percent nocte), with a short course of a topical corticosteroid for acute itch.^[1]

The same patient returns with painful nodules, abscesses, and ropelike sinus tracks in the axillae and groin. What changed, and what do you do?ShowHide

The symptom has flipped from pruritus to pain and sinus tracts have appeared — the cardinal signs of hidradenitis suppurativa, not Fox-Fordyce. Move to the HS pathway (Hurley staging, topical and systemic anti-inflammatory and antibiotic therapy, biological and surgical options) rather than escalating Fox-Fordyce therapy on a wrong diagnosis.^[1]

Name the histological triad of Fox-Fordyce disease and the single anatomy fact that explains its distribution.ShowHide

The triad is apocrine duct spongiosis at the intra-epidermal duct entry, a parakeratotic plug in the follicular infundibulum, and a dilated duct or retention cyst filled with secretion and foam cells. The anatomy fact is that the apocrine duct empties into the hair follicle (unlike the eccrine duct, which opens onto the skin surface) — which is why the disease is follicular, why the hair is shed, why the skin is anhidrotic, and why it never leaves apocrine territory.^[3]

A 30-year-old with refractory Fox-Fordyce is started on oral isotretinoin. What two safeguards are non-negotiable, and what should you warn her about in the first weeks?ShowHide

Isotretinoin is Category X and teratogenic in precisely the reproductive-age population most affected — so two methods of contraception plus pregnancy testing before, during, and after therapy are mandatory, with lipid and liver monitoring. Warn her that a paradoxical initial flare is recognised and may need a short course of oral prednisolone cover, and that recurrence after stopping is the rule.^[2]

References12ShowHide

1. [1]Litchman G, Sonthalia S Fox-Fordyce Disease (Apocrine Miliaria) 2026.PMID 31424791
2. [2]Miao C, Zhang H, Zhang M, et al. Fox-Fordyce disease An Bras Dermatol, 2018.PMID 29641729
3. [3]Blasco-Morente G, Naranjo-Díaz MJ, Pérez-López I, et al. Fox-Fordyce Disease Sultan Qaboos Univ Med J, 2016.PMID 26909204
4. [4]Singal A, Kaur I, Jakhar D Fox-Fordyce Disease: Dermoscopic Perspective Skin Appendage Disord, 2020.PMID 32903893
5. [5]Dowling GB Fox-Fordyce Disease Proc R Soc Med, 1936.PMID 19990737
6. [6]George A, Bhatia A, Thomas E Fox-Fordyce disease: a report of 2 cases responding to topical clindamycin Indian J Dermatol Venereol Leprol, 2015.PMID 25566917
7. [7]Kassuga LE, Medrado MM, Chevrand NS, et al. Fox-Fordyce disease: response to adapalene 0.1% An Bras Dermatol, 2012.PMID 22570049
8. [8]Milcic D, Nikolic M Clinical effects of topical pimecrolimus in a patient with Fox-Fordyce disease Australas J Dermatol, 2012.PMID 22571582
9. [9]Kaya Erdogan H, Bulur I, Kaya Z Clinical Effects of Topical Tacrolimus on Fox-Fordyce Disease Case Rep Dermatol Med, 2015.PMID 26171257
10. [10]Effendy I, Ossowski B, Happle R Fox-Fordyce disease in a male patient — response to oral retinoid treatment Clin Exp Dermatol, 1994.PMID 8313643
11. [11]González-Ramos J, Alonso-Pacheco ML, Goiburú-Chenú B, et al. Successful treatment of refractory pruritic Fox-Fordyce disease with botulinum toxin type A Br J Dermatol, 2016.PMID 26385128
12. [12]Ahmed Al-Qarqaz F, Al-Shannag R Fox-Fordyce disease treatment with fractional CO2 laser Int J Dermatol, 2013.PMID 24261728